Abstract (EN):
The objective of this study was to define the type of patient who can benefit from treatment with Iloprost, a stable analogue of PGI2. Nine patients were studied in Oporto, three female and six male, between 26 and 86 years of age (average age=58). Of the six patients with stage IV (Fontaine) ischaemia, two were diabetics and three presented clinical, arteriographic and histological criteria of T.A.O.; there were no trophic lesions in three cases, rest pain being the main symptom (stage III ischaemia). The efficacy parameters consisted of: the diminution of rest pain, the reduction of analgesic consumption and the clinical improvement of ischaemic ulcers and necroses. Additionally, the tolerance for the drug under study was assessed. Of six patients with trophic lesions, two presented complete cicatrisation after a first period of infusion (24 and 56 days), one partial cicatrisation (>50%), two stabilized the evolution of the lesions and in one the condition deteriorated. At the beginning of the therapy, all patients had rest pain and required analgesics, these were suspended during treatment in seven cases and the dose greatly reduced in two. A succinct analysis of the results obtained from this sample suggests the benefit of use of Iloprost, in patients with stage III or IV ischaemia, in the impossibility of surgical revascularization.
Language:
Portuguese
Type (Professor's evaluation):
Scientific
Contact:
José Teixeira